X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/sorrento-therapeutics-inc-announces-the-consummation-of-the-previously-announced-sale-of-substantially-all-of-the-common-shares-preferred-shares-and-warrants-that-sorrento-held-in-scilex-holding-company-301936341.html
https://endpts.com/sorrento-goes-to-china-with-covid-drug-vistagen-touts-early-efficacy-data-on-pmdd-nasal-spray/
https://www.globenewswire.com//news-release/2023/09/12/2741721/0/en/Sorrento-Announces-Phase-3-Trial-Met-Primary-Endpoint-and-Key-Secondary-Endpoint-in-Mild-or-Moderate-COVID-19-Adult-Patients-Treated-with-Ovydso-Olgotrelvir-an-Oral-Mpro-Inhibitor-.html
https://www.globenewswire.com//news-release/2023/09/07/2739412/0/en/Sorrento-Therapeutics-Announces-Positive-Phase-2a-Clinical-Trial-Results-for-Resiniferatoxin-RTX-for-the-Treatment-of-Knee-Pain-in-Moderate-to-Severe-Osteoarthritis-of-the-Knee-OAK.html
https://www.prnewswire.com/news-releases/sorrento-therapeutics-inc-announces-auction-for-sale-of-scilex-securities-and-bankruptcy-court-approval-of-stalking-horse-bid-301895801.html
https://www.globenewswire.com/news-release/2023/07/27/2712264/0/en/Sorrento-Issues-a-FAQ-in-Response-to-Large-Number-Of-Urgent-Requests-from-Scilex-Dividend-Short-Holders-and-or-Record-Holders.html
https://www.prnewswire.com/news-releases/sorrento-announces-launch-of-voluntary-offering-to-dividend-short-holders-with-deadline-to-participate-by-july-27-2023-301882982.html
https://www.globenewswire.com/news-release/2023/07/05/2699555/0/en/Sorrento-Announces-Positive-Phase-IIa-Study-Results-of-Abivertinib-for-the-Treatment-of-Relapsed-Refractory-Marginal-Zone-Lymphoma-R-R-MZL-and-Its-Plan-for-a-Pivotal-Phase-III-Stud.html
https://www.globenewswire.com/news-release/2023/06/26/2694495/0/en/Sorrento-Announces-the-Full-Enrollment-of-the-Pivotal-Phase-3-Trial-with-Olgotrelvir-OVYDSOTM-STI-1558-a-Second-Generation-Oral-Mpro-Inhibitor-as-a-Standalone-Treatment-for-COVID-1.html
Market Place
Share 
